Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

2.

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S.

Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570-4. [Epub ahead of print]

PMID:
29124456
3.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, Boulad F, Castro-Malaspina H, Tamari R, Dahi PB, Goldberg J, Koehne G, Perales MA, Sauter CS, O'Reilly RJ, Giralt S.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1685-1694. doi: 10.1016/j.bbmt.2017.06.024. Epub 2017 Jul 19.

PMID:
28734876
4.

ER retention is imposed by COPII protein sorting and attenuated by 4-phenylbutyrate.

Ma W, Goldberg E, Goldberg J.

Elife. 2017 Jun 8;6. pii: e26624. doi: 10.7554/eLife.26624.

5.

Survival, Healthcare Utilization, and End-of-life Care Among Older Adults With Malignancy-associated Bowel Obstruction: Comparative Study of Surgery, Venting Gastrostomy, or Medical Management.

Lilley EJ, Scott JW, Goldberg JE, Cauley CE, Temel JS, Epstein AS, Lipsitz SR, Smalls BL, Haider AH, Bader AM, Weissman JS, Cooper Z.

Ann Surg. 2017 Feb 1. doi: 10.1097/SLA.0000000000002164. [Epub ahead of print]

PMID:
28151799
6.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

PMID:
28073320
7.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

PMID:
28017734
8.

TANGO1/cTAGE5 receptor as a polyvalent template for assembly of large COPII coats.

Ma W, Goldberg J.

Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10061-6. doi: 10.1073/pnas.1605916113. Epub 2016 Aug 22.

9.

A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.

Hobbs GS, Kaur N, Hilden P, Ponce D, Cho C, Castro-Malaspina HR, Giralt S, Goldberg JD, Jakubowski AA, Papadopoulos EB, Sauter C, Koehne G, Yahalom J, Delvin S, Barker JN, Perales MA.

Bone Marrow Transplant. 2016 Jul;51(7):1010-2. doi: 10.1038/bmt.2016.36. Epub 2016 Mar 14. No abstract available.

10.

Palliative Care and Symptom Management in Older Patients with Cancer.

Alexander K, Goldberg J, Korc-Grodzicki B.

Clin Geriatr Med. 2016 Feb;32(1):45-62. doi: 10.1016/j.cger.2015.08.004. Epub 2015 Oct 17. Review.

11.

Cell cycle features of C. elegans germline stem/progenitor cells vary temporally and spatially.

Roy D, Michaelson D, Hochman T, Santella A, Bao Z, Goldberg JD, Hubbard EJ.

Dev Biol. 2016 Jan 1;409(1):261-71. doi: 10.1016/j.ydbio.2015.10.031. Epub 2015 Nov 11.

12.

CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2106-2114. doi: 10.1016/j.bbmt.2015.07.010. Epub 2015 Jul 14.

13.

Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83. doi: 10.1016/j.bbmt.2015.04.016. Epub 2015 May 11.

14.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

15.

Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.

Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P.

Bone Marrow Transplant. 2015 Apr;50(4):493-8. doi: 10.1038/bmt.2014.302. Epub 2015 Jan 26.

16.

Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.

Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, Perales MA.

Bone Marrow Transplant. 2015 Mar;50(3):438-43. doi: 10.1038/bmt.2014.286. Epub 2015 Jan 19.

17.

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021. Epub 2014 Oct 30.

18.

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop SE, O'Reilly RJ, Scaradavou A, Paczesny S, Barker JN.

Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.

19.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28.

20.

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.

Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, Perales MA.

Leuk Lymphoma. 2015 Mar;56(3):663-70. doi: 10.3109/10428194.2014.930851. Epub 2014 Aug 6.

Supplemental Content

Loading ...
Support Center